|Age:||18 years or older|
|Keywords:||advanced stage solid tumor cancer, solid tumor cancer, tumor cancer, cancer, NSCLC, non small cell lung cancer, melanoma, renal cell carcinoma, head and neck squamous cell carcinoma|
|Type:||Drug study, Phase [1, 2]|
If you agree to take part in this study, you will undergo tests and procedures to ensure you qualify to join the study. These tests and procedures will be explained to you in greater detail by the study team.
Your doctor will assess your condition at the following time points: - once during the first week of radiotherapy - during each IL-2 injection - every three weeks during the first nine weeks and every 30 days during follow-up o A complete physical examination will be performed. This will include measuring your vital signs (blood pressure, breathing rate, pulse, body temperature), and recording your height and weight o An evaluation of your ability to carry out daily activities
every three weeks afterwards until end of treatment o Blood will be drawn for routine safety laboratory tests (including blood cell counts, liver and kidney functions, blood clotting ability, and your thyroid function). •Blood will be drawn to study biomarkers related to immune function and level of inflammation in the body – which will require 2-3 tablespoons of blood each time. You will be asked to undergo a tumor biopsy at week 6.
Starting at Week 1: You will be given a checkpoint blockade immunotherapy (CBI) drug called pembrolizumab during week 1 and will continue every three weeks. This drug is given by intravenous infusion over 30 minutes for each treatment. These treatments will last for up to six months.
Week 4-6: Three radiation treatments will be given 12–96 hours apart during weeks 4-6 of treatment. Radiation will be delivered directly into the tumor we are treating with IL-2. If you have more than one tumor, only the tumor treated with IL-2 will undergo radiation.e. Your doctor will explain the radiation treatments and your schedule with you.
Week 1 and 5: Interleukin-2 (IL-2) will be injected directly into your cancerous lesion 4 times (2 injections on weeks 1 and 5 with each injection at least two days apart), starting 24-96 hours after completion of radiotherapy.
Once during weeks 7-9 and every 30 days afterwards, until the end of follow-up, all sites of your cancer will be scanned using computed tomography (CT) or magnetic resonance imaging (MRI).
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.